Alzheimer’s Disease Preclinical Efficacy Database (AlzPED): Optimizing the Scientific Rigor and Reproducibility of Preclinical Research in Alzheimer’s Disease

Assessments of preclinical animal studies in Alzheimer’s disease (AD) highlight the lack of methodological rigor and inadequate reporting practices as contributive to the preclinical to clinical translation gap in AD therapy development. The Alzheimer’s Disease Preclinical Efficacy Database (AlzPED), a searchable and publicly available knowledgebase developed by the National Institute on Aging aims to illuminate key elements of experimental design and reporting practices of preclinical efficacy testing studies for researchers, funding agencies, and the public. The database is missioned to improve transparency in reporting, increase awareness of the need for greater rigor in study design, and identify critical experimental design elements and methodology missing from studies that make them susceptible to over‐interpretation and reduce their reproducibility and translational value.